International Assets Investment Management LLC Raises Holdings in United Therapeutics Co. (NASDAQ:UTHR)

International Assets Investment Management LLC increased its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 13,769.2% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 9,015 shares of the biotechnology company’s stock after acquiring an additional 8,950 shares during the period. International Assets Investment Management LLC’s holdings in United Therapeutics were worth $1,982,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Atlas Capital Advisors LLC purchased a new position in United Therapeutics in the fourth quarter worth approximately $51,000. Northwestern Mutual Wealth Management Co. grew its position in United Therapeutics by 49.6% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 196 shares of the biotechnology company’s stock worth $55,000 after acquiring an additional 65 shares during the period. Neo Ivy Capital Management purchased a new position in United Therapeutics in the second quarter worth approximately $48,000. Zions Bancorporation N.A. purchased a new position in United Therapeutics in the first quarter worth approximately $66,000. Finally, Quantbot Technologies LP purchased a new position in United Therapeutics in the second quarter worth approximately $87,000. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, EVP Paul A. Mahon sold 6,000 shares of the firm’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $215.31, for a total value of $1,291,860.00. Following the sale, the executive vice president now directly owns 36,599 shares in the company, valued at $7,880,130.69. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other United Therapeutics news, EVP Paul A. Mahon sold 6,000 shares of the firm’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $215.31, for a total value of $1,291,860.00. Following the sale, the executive vice president now directly owns 36,599 shares in the company, valued at $7,880,130.69. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Christopher Patusky sold 1,680 shares of the firm’s stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $224.00, for a total value of $376,320.00. Following the completion of the sale, the director now owns 4 shares in the company, valued at $896. The disclosure for this sale can be found here. Insiders have sold a total of 129,790 shares of company stock worth $30,528,633 over the last ninety days. Corporate insiders own 12.50% of the company’s stock.

United Therapeutics Stock Up 0.4 %

Shares of NASDAQ UTHR opened at $237.93 on Friday. The stock has a market cap of $11.20 billion, a P/E ratio of 11.99 and a beta of 0.52. The company has a current ratio of 4.41, a quick ratio of 4.28 and a debt-to-equity ratio of 0.05. United Therapeutics Co. has a 12-month low of $204.44 and a 12-month high of $261.54. The business’s fifty day simple moving average is $231.71 and its 200-day simple moving average is $228.55.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.28 by $0.08. The business had revenue of $614.70 million for the quarter, compared to analysts’ expectations of $575.01 million. United Therapeutics had a return on equity of 17.72% and a net margin of 42.31%. The company’s revenue for the quarter was up 25.1% compared to the same quarter last year. During the same period last year, the firm earned $2.67 earnings per share. As a group, equities analysts predict that United Therapeutics Co. will post 23.46 EPS for the current fiscal year.

Wall Street Analyst Weigh In

UTHR has been the subject of several analyst reports. StockNews.com lowered United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, April 11th. The Goldman Sachs Group upgraded United Therapeutics from a “sell” rating to a “neutral” rating and upped their price target for the stock from $213.00 to $215.00 in a research note on Monday, February 12th. HC Wainwright restated a “buy” rating and set a $300.00 price target on shares of United Therapeutics in a research note on Thursday, February 22nd. Wells Fargo & Company upped their price target on United Therapeutics from $309.00 to $325.00 and gave the stock an “overweight” rating in a research note on Thursday, March 7th. Finally, SVB Leerink started coverage on United Therapeutics in a research note on Monday, February 5th. They set an “outperform” rating and a $330.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $292.67.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.